Cipla USA Inc received final US FDA approval for its AB-rated generic Albuterol Sulfate Inhalation Aerosol, equivalent to Ventolin HFA.
The product addresses a $1.5 billion US albuterol market and will be launched in H1 FY2026-27 from Cipla's Massachusetts facility.
This approval strengthens Cipla's US respiratory portfolio and demonstrates its complex inhalation product capabilities.